<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydrocodone and phenyltoloxamine (United States and Canada: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydrocodone and phenyltoloxamine (United States and Canada: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydrocodone and phenyltoloxamine (United States and Canada: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="89333" href="/d/html/89333.html" rel="external">see "Hydrocodone and phenyltoloxamine (United States and Canada: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16361831"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alkylamine Derivative;</li>
<li>
                        Analgesic, Opioid;</li>
<li>
                        Antitussive;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, First Generation</li></ul></div>
<div class="block doa drugH1Div" id="F16368925"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8346390e-4525-44ea-9ee2-d63be2ed68b3">Cough</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough:</b>
<b>Oral:</b> Suspension (hydrocodone 5 mg and phenyltoloxamine 10 mg per 5 mL): 5 mL every 8 to 12 hours for ≤7 days; maximum: 10 mL (hydrocodone 10 mg/phenyltoloxamine 20 mg) per day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block doe drugH1Div" id="F16368926"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F16361840"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Drowsiness, drug dependence, hallucination, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Facial pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Constipation, nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Hypogonadism (Brennan 2013; Debono 2011)</p></div>
<div class="block coi drugH1Div" id="F16361836"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydrocodone, phenyltoloxamine, or any component of the formulation; known or suspected GI obstruction (eg, bowel obstruction or strictures) or any disease/condition that affect bowel transit (eg, ileus of any type); surgical abdomen, including acute appendicitis or pancreatitis; acute or severe bronchial asthma; chronic obstructive airway; status asthmaticus; marked hypertension; acute alcoholism; delirium tremens; convulsive disorders; monoamine oxidase inhibitors (concurrent use or within 14 days of therapy); acute respiratory depression; hypercapnia; cor pulmonale; severe CNS depression; increased cerebrospinal or intracranial pressure; head injury; children &lt;6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F16361837"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostasis and syncope); risk is increased in patients with reduced blood volume or taking concurrent CNS depressants (eg, phenothiazines, general anesthetics). Avoid use in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (eg, codeine, hydromorphone, levorphanol, morphine, oxycodone, oxymorphone).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: <b>[Canadian Boxed Warning]:</b>
<b>Serious, life-threatening, or fatal respiratory depression may occur with hydrocodone. Patients should be aware of the hazards related to taking opioids including fatal overdose. </b>
<b>Patients should be monitored for respiratory depression, especially during initiation or following a dose increase </b>(including patients with chronic pulmonary disease, decreased respiratory reserve, altered pharmacokinetics or clearance, and in patients taking concurrent drugs that may cause respiratory depression)<b>.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Rare, but potentially life-threatening, serotonin syndrome may occur from concomitant use of serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors). Do not use in combination with monoamine oxidase inhibitors or serotonin precursors (eg, l-tryptophan, oxitriptan); use with caution in combination with other serotonergic agents (eg, triptans, tricyclic antidepressants, lithium, tramadol, St John's wort). Discontinue treatment immediately if signs/symptoms arise.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Use is contraindicated with known or suspected obstruction or any disease/condition that affect bowel transit (eg, ileus of any type).</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use hydrocodone with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, exaggerated elevation of ICP may occur. Use is contraindicated in patients with intracranial lesions with increased intracranial pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease: Use with caution in patients with peripheral vascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with pulmonary disease or decreased ventilatory function; dose-related respiratory depression occurs. Use is contraindicated in patients with acute or chronic bronchial asthma, status asthmaticus, chronic obstructive airway, acute respiratory depression, hypercapnia, and cor pulmonale.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure: Use is contraindicated in patients with a history of seizure disorder; may cause or exacerbate preexisting seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol: <b>[Canadian Boxed Warning]:</b>
<b>The co-ingestion of alcohol should be avoided as it may result in dangerous additive effects, causing serious injury or death.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzodiazepines or other CNS depressants:<b> [Canadian Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of hydrocodone/phenyltoloxamine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required and monitor patients for signs and symptoms of respiratory depression and sedation. </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2D6 poor or intermediate metabolizers: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), CYP2D6 poor and intermediate metabolizers may have decreased hydromorphone formation. However, limited data exist to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (CPIC [Crews 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; may be more sensitive to adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Neonatal withdrawal syndrome:<b> [Canadian Boxed Warning]: Prolonged maternal use of hydrocodone/phenyltoloxamine during pregnancy can cause neonatal opioid withdrawal syndrome, which may be life-threatening. </b>Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not indicated in pediatric patients &lt;18 years due to risk of adverse effects; use in children &lt;6 years of age has been associated with fatal respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: <b>[Canadian Boxed Warning]:</b>
<b>Hydrocodone/phenyltoloxamine poses risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient's risk should be assessed prior to prescribing hydrocodone/phenyltoloxamine, and all patients should be monitored regularly for the development of these behaviors or conditions. Hydrocodone/phenyltoloxamine should be stored securely to avoid theft or misuse. </b>Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists; do not abruptly discontinue in a physically-dependent patient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental exposure:<b> [Canadian Boxed Warning]: Accidental exposure to hydrocodone/phenyltoloxamine, especially in children, can result in a fatal overdose of hydrocodone. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[Canadian Boxed Warning]: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with controlled release opioid formulations, hydrocodone/phenyltoloxamine should only be used in patients for whom alternative non-opioid treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide appropriate cough management</b>. Underlying cause of cough should be determined prior to prescribing. Do not dilute in other liquids or mix with other drugs; may alter resin-binding and change absorption rate which can increase risk of toxicity. Accurate measuring devices should be used to measure suspension doses. Calibrated oral syringes are most accurate.</p></div>
<div class="block prod-avail drugH1Div" id="F16368930"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Tussionex represents a different product in Canada than it does in the US. In Canada, Tussionex contains hydrocodone and phenyltoloxamine while in the US Tussionex (Pennkinetic) contains hydrocodone and chlorpheniramine.</p></div>
<div class="block geq drugH1Div" id="F53040760"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block csi drugH1Div" id="F16361828"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">CDSA I</p></div>
<div class="block adm drugH1Div" id="F16368928"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Do not dilute with fluid or mix with other medications. Shake suspension well before using; use calibrated oral syringe to measure doses.</p></div>
<div class="block use drugH1Div" id="F16361833"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough:</b> Symptomatic relief of exhausting or nonproductive cough associated with cold or upper respiratory allergies that does not respond to nonopioid antitussives</p></div>
<div class="block mst drugH1Div" id="F16361827"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tussionex represents a different product in Canada than it does in the US. In Canada, Tussionex contains hydrocodone and phenyltoloxamine while in the US Tussionex (Pennkinetic) contains hydrocodone and chlorpheniramine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Based on pharmacologic class concerns for first-generation antihistamines in the Beers Criteria phenyltoloxamine may be a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F17917949"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F17917947"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodone. Management: Patients using hydrocodone extended-release capsules must not consume alcohol or alcohol-containing products due to possibly fatal outcomes. Other hydrocodone products are also expected to interact, but to a less significant degree.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of HYDROcodone. HYDROcodone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Consider alternatives to this combination when possible. If coadministration is required, use test doses, titrate small doses frequently, and monitor patients closely for evidence of serotonergic and opioid toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Opioid Agonists (metabolized by CYP3A4 and CYP2D6) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4 and CYP2D6).  Management: Monitor for increased opioid effects, including fatal respiratory depression, when these agents are combined and consider opioid dose reductions until stable drug effects are achieved. Additionally, monitor for serotonin syndrome/serotonin toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of HYDROcodone. Management: Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, and ritonavir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of HYDROcodone. Management: Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, ritonavir, and dasabuvir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of HYDROcodone. PHENobarbital may decrease the serum concentration of HYDROcodone. Management: Avoid use of hydrocodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased hydrocodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of HYDROcodone. Primidone may decrease the serum concentration of HYDROcodone. Management: Avoid use of hydrocodone and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased hydrocodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): Opioid Agonists (metabolized by CYP3A4 and CYP2D6) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of Opioid Agonists (metabolized by CYP3A4 and CYP2D6).  Management: Monitor for decreased therapeutic response (eg, analgesia) and opioid withdrawal when coadministered with SSRIs that strongly inhibit CYP2D6. Additionally, monitor for serotonin syndrome/serotonin toxicity if these drugs are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4 and CYP2D6) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307486"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction and infertility (Brennan 2013).</p></div>
<div class="block pri drugH1Div" id="F51721954"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[Canadian Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available</b>.</p>
<p style="text-indent:0em;margin-top:2em;">
<b></b>Refer to the hydrocodone monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F51721955"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Hydrocodone is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F52468194"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Relief of symptoms, respiratory and mental status; bowel function; signs/symptoms of substance use disorder, abuse, or misuse</p></div>
<div class="block pha drugH1Div" id="F16361850"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Hydrocodone binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression.</p>
<p style="text-indent:-2em;margin-left:2em;">Phenyltoloxamine competes with histamine for H<sub>1</sub>-receptor sites on effector cells. May potentiate the antitussive effects of hydrocodone; sedative effects are also seen.</p></div>
<div class="block phk drugH1Div" id="F16361852"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Antitussive effects: ≥8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrocodone: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson 2004; Volpe 2011; Zhou 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Hydrocodone: ~4 hours (Tussionex Pennkinetic US prescribing information 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Hydrocodone: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol [Zhou 2009])</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58209696"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tussionex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17661614">
<a name="17661614"></a>Anderson PO, Sauberan JB, Lane JR, et al. Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases. <i>Breastfeed Med</i>. 2007;2(1):10-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/17661614/pubmed" id="17661614" target="_blank">17661614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi:10.1016/j.amjmed.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21345403">
<a name="21345403"></a>Broussard CS, Rasmussen SA, Reefhuis J, et al. National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects. <i>Am J Obstet Gynecol</i>. 2011;204(4):314.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/21345403/pubmed" id="21345403" target="_blank">21345403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33387367">
<a name="33387367"></a>Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. <i>Clin Pharmacol Ther</i>. 2021;110(4):888-896. doi:10.1002/cpt.2149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/33387367/pubmed" id="33387367" target="_blank">33387367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21243342">
<a name="21243342"></a>Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol.</i> 2011;67(8):865-867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/21243342/pubmed" id="21243342" target="_blank">21243342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. Available at: <a href="https://www.fda.gov/Drugs/DrugSafety/ucm590435.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm590435.htm</a>. Published January 11, 2018. Accessed February 5, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998425">
<a name="14998425"></a>Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes. <i>Br J Clin Pharmacol</i>. 2004;57(3):287-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/14998425/pubmed" id="14998425" target="_blank">14998425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, et al. Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20407360">
<a name="20407360"></a>Molina DK, Hargrove VM. What Is the Lethal Concentration of Hydrocodone? <i>Am J Forensic Med Pathol</i>. 2011;32(2):108-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/20407360/pubmed" id="20407360" target="_blank">20407360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9356103">
<a name="9356103"></a>Rathmell JP, Viscomi CM, Ashburn MA. Management of Nonobstetric Pain During Pregnancy and Lactation. <i>Anesth Analg</i>. 1997;85(5):1074-1087.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/9356103/pubmed" id="9356103" target="_blank">9356103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343764">
<a name="21343764"></a>Sauberan JB, Anderson PO, Lane JR, et al. Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain. <i>Obstet Gynecol</i>. 2011;117(3):611-617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/21343764/pubmed" id="21343764" target="_blank">21343764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tussionex.1">
<a name="Tussionex.1"></a>Tussionex Pennkinetic [US prescribing information]. Smyrna, GA: UCB Inc, January 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tussionex.2">
<a name="Tussionex.2"></a>Tussionex (hydrocodone and phenyltoloxamine) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21215785">
<a name="21215785"></a>Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs. <i>Regul Toxicol Pharmacol</i>. 2011;59(3):385-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/21215785/pubmed" id="21215785" target="_blank">21215785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19902987">
<a name="19902987"></a>Zhou SF. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II. <i>Clin Pharmacokinet</i>. 2009;48(12):761-804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocodone-and-phenyltoloxamine-united-states-and-canada-not-available-drug-information/abstract-text/19902987/pubmed" id="19902987" target="_blank">19902987</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 88816 Version 243.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
